BeOne Medicines CEO John Oyler reports disposal of shares worth $75.72 millionPUBT·Jul 17 at 04:31 PM06160-1.07%BGNE0.00%
SystImmune Announces Second Approval of Iza-bren in China for the Treatment of Recurrent or Metastatic Esophageal Squamous Cell CarcinomaUnusual Whales·Jul 17 at 07:27 AM688506-2.93%02615
Macquarie Raises BEONE MEDICINES TP to HKD257, Reiterates Outperform RatingAASTOCKS News·Jul 13 at 03:20 AMONC-1.88%06160-1.07%
Analyst Reiterates Buy on BeiGene, Lifts Brukinsa-Driven Outlook and Raises Price Target to $380 Amid Pipeline ProgressTip Ranks·Jul 12 at 07:25 PM06160-1.07%688235-0.95%
Transthera wins China NMPA clearance for Phase II TT-00973 combo trial in EGFR-mutant NSCLCPUBT·Jul 10 at 09:18 AM688578-3.77%
Huafu Securities Sticks to Its Buy Rating for BeOne Medicines Ltd (6160)Tip Ranks·Jul 7 at 12:15 AMONC-1.88%BGNE0.00%
BeOne Medicines Chief Executive Officer Sold Shares Worth Over $933KTradingView·Jun 25 at 04:20 PM688235-0.95%ONC-1.88%
China’s Biokin Soars After Its First-in-Class Cancer Drug Is Greenlit for Chinese Market LaunchYicai·Jun 23 at 01:26 AM688506-2.93%BMY+0.69%
BeOne Medicines Executives Quietly Cash In on a Wave of Insider Stock SalesTip Ranks·Jun 18 at 09:06 PMONC-1.88%688235-0.95%
15:07 ETSystImmune Announces First Approval of Iza-bren for the Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma in Chinaprnewswire·Jun 22 at 02:09 PM688506-2.93%02615
BeOne Medicines Sets Out Board and Committee Structure to Bolster GovernanceTip Ranks·Jun 11 at 06:04 PMBGNE0.00%06160-1.07%
BeOne Medicines Files U.S. Form S-8 to Expand Equity Incentive PlansTip Ranks·Jun 11 at 06:05 PM06160-1.07%688235-0.95%
Global's June 2026 Stocks Possibly Priced Below Fair ValueSimplywall·Jun 11 at 04:20 AM3046688617+3.47%
